Diffuse Hemispheric Glioma with H3 P.K28M (K27M) Mutation: Unusual Non-midline Presentation of Diffuse Midline Glioma, H3 K27M-altered?
Overview
Authors
Affiliations
Diffuse midline glioma, H3 K27-altered (DMG-H3 K27) is an aggressive group of diffuse gliomas that predominantly occurs in pediatric patients, involves midline structures, and displays loss of H3 p.K28me3 (K27me3) expression by immunohistochemistry and characteristic genetic/epigenetic profile. Rare examples of a diffuse glioma with an H3 p.K28M (K27M) mutation and without involvement of the midline structures, so-called "diffuse hemispheric glioma with H3 p.K28M (K27M) mutation" (DHG-H3 K27), have been reported. Herein, we describe 2 additional cases of radiologically confirmed DHG-H3 K27 and summarize previously reported cases. We performed histological, immunohistochemical, molecular, and DNA methylation analysis and provided clinical follow-up in both cases. Overall, DHG-H3 K27 is an unusual group of diffuse gliomas that shows similar clinical, histopathological, genomic, and epigenetic features to DMG-H3 K27 as well as enrichment for activating alterations in MAPK pathway genes. These findings suggest that DHG-H3 K27 is closely related to DMG-H3 K27 and may represent an unusual presentation of DMG-H3 K27 without apparent midline involvement and with frequent MAPK pathway activation. Detailed reports of additional cases with clinical follow-up will be important to expand our understanding of this unusual group of diffuse gliomas and to better define the clinical outcome and how to classify DHG-H3 K27.
Broggi G, Salzano S, Failla M, Barbagallo G, Certo F, Zanelli M Diagnostics (Basel). 2024; 14(23).
PMID: 39682526 PMC: 11640674. DOI: 10.3390/diagnostics14232617.
Methylation assay in KMT2B-related dystonia: a novel diagnostic validation tool.
da Silva Carvalho G, de Gusmao C, Wolff B, Vieira L, de Oliveira Y, Costa M Clin Epigenetics. 2024; 16(1):169.
PMID: 39587624 PMC: 11590325. DOI: 10.1186/s13148-024-01780-1.
Angelico G, Mazzucchelli M, Attanasio G, Tinnirello G, Farina J, Zanelli M Cancers (Basel). 2024; 16(20).
PMID: 39456545 PMC: 11506073. DOI: 10.3390/cancers16203451.
Fulminant leptomeningeal disease diagnosed as comutant H3F3A and FGFR diffuse midline glioma.
Benistant L, Reita D, Schenck M, Castelain V, Cebula H, Lhermitte B Ann Clin Transl Neurol. 2024; 11(11):3037-3041.
PMID: 39440520 PMC: 11572734. DOI: 10.1002/acn3.52180.